AR128688A1 - Anticuerpos anti-cd39 y uso de los mismos - Google Patents
Anticuerpos anti-cd39 y uso de los mismosInfo
- Publication number
- AR128688A1 AR128688A1 ARP230100529A ARP230100529A AR128688A1 AR 128688 A1 AR128688 A1 AR 128688A1 AR P230100529 A ARP230100529 A AR P230100529A AR P230100529 A ARP230100529 A AR P230100529A AR 128688 A1 AR128688 A1 AR 128688A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- complementarity determining
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 17
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 6
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 101100501552 Homo sapiens ENTPD1 gene Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan anticuerpos anti-CD39 que inhiben la actividad enzimática de CD39 humana y métodos de uso de los mismos. Reivindicación 1: Un anticuerpo anti-CD39 que se une específicamente a CD39 humana, que comprende (a) una región variable de cadena pesada que comprende una región determinante de la complementariedad 1 (H1) que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 10, una región determinante de la complementariedad 2 (H2) que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 11, y una región determinante de la complementariedad 3 (H3) que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 12; y una región variable de cadena ligera que comprende una región determinante de la complementariedad 1 (L1) que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 14, una región determinante de la complementariedad 2 (L2) que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 15, y una región determinante de la complementariedad 3 (L3) que tiene una secuencia de aminoácidos que comprende la ID Nº 16; (b) una región variable de cadena pesada que comprende una H1 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 18, una H2 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 19, y una H3 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 20; y una región variable de cadena ligera que comprende una L1 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 22, SEQ ID Nº 23, o la SEQ ID Nº 24, una L2 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 25, y una L3 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 26; o (c) una región variable de cadena pesada que comprende una H1 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 28, una H2 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 29, y una H3 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 30; y una región variable de cadena ligera que comprende una L1 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 32, una L2 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 33, y una L3 que tiene una secuencia de aminoácidos que comprende la SEQ ID Nº 34. Reivindicación 48: Una composición farmacéutica que comprende el anticuerpo de cualquiera de las reivindicaciones 1 - 20 y un portador farmacéuticamente aceptable. Reivindicación 49: Un polinucleótido aislado que codifica el anticuerpo de cualquiera de las reivindicaciones 1 - 20. Reivindicación 50: Un vector que comprende el polinucleótido aislado de la reivindicación 49. Reivindicación 51: Una célula huésped que comprende el vector de la reivindicación 50. Reivindicación 52: Un método para expresar el anticuerpo de cualquiera de las reivindicaciones 1 - 20, que comprende cultivar la célula huésped de la reivindicación 51 bajo la condición en la que el polinucleótido de la reivindicación 49 se expresa. Reivindicación 53: Un kit que comprende el anticuerpo de cualquiera de las reivindicaciones 1 - 20.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2022/079021 WO2023164872A1 (en) | 2022-03-03 | 2022-03-03 | Anti-cd39 antibodies and use thereof |
| CN2022126070 | 2022-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128688A1 true AR128688A1 (es) | 2024-06-05 |
Family
ID=87883061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100529A AR128688A1 (es) | 2022-03-03 | 2023-03-02 | Anticuerpos anti-cd39 y uso de los mismos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11970543B2 (es) |
| EP (1) | EP4486785A1 (es) |
| KR (1) | KR20240156633A (es) |
| CN (1) | CN119173535A (es) |
| AR (1) | AR128688A1 (es) |
| AU (1) | AU2023227964A1 (es) |
| IL (1) | IL315351A (es) |
| MX (1) | MX2024010646A (es) |
| TW (1) | TW202340243A (es) |
| WO (1) | WO2023165561A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024115966A2 (en) * | 2022-12-01 | 2024-06-06 | Innate Pharma | Compositions and methods for neoadjuvant treatment in cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2238170T (pt) | 2008-01-31 | 2017-02-21 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | Anticorpos contra cd39 humano e seu uso para inibição da actividade de células t reguladoras |
| DK2654789T3 (en) | 2010-12-22 | 2018-09-03 | Orega Biotech | ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF |
| US10556959B2 (en) | 2014-11-07 | 2020-02-11 | Xencor, Inc. | Anti-CD39 antibodies and uses thereof |
| JP2019509014A (ja) | 2015-11-23 | 2019-04-04 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | Ｃｄ３９血管アイソフォームターゲティング剤 |
| EP3912681A1 (en) | 2016-03-14 | 2021-11-24 | Orega Biotech | Anti-cd39 antibodies |
| ES2820173T3 (es) | 2016-05-06 | 2021-04-19 | Inst Nat Sante Rech Med | Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente |
| WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
| KR102584011B1 (ko) | 2017-03-16 | 2023-09-27 | 이나뜨 파르마 에스.에이. | 암 치료를 위한 조성물 및 방법 |
| SG10202111869SA (en) | 2017-07-31 | 2021-11-29 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| SG11202002192QA (en) | 2017-10-06 | 2020-04-29 | Innate Pharma | Restoration of t cell activity via the cd39/cd73 axis |
| EP3710052A1 (en) | 2017-11-15 | 2020-09-23 | Innate Pharma | Potentiating the effect of atp release |
| MX2021015518A (es) | 2018-03-14 | 2022-07-21 | Surface Oncology Inc | Anticuerpos que se unen a cd39 y sus usos. |
| US20210253731A1 (en) | 2018-06-14 | 2021-08-19 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition and antibody-mediated target cytosis |
| SG11202012435UA (en) | 2018-06-18 | 2021-01-28 | Innate Pharma | Compositions and methods for treating cancer |
| US20230242660A1 (en) | 2019-02-21 | 2023-08-03 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies |
| US12098212B2 (en) | 2019-08-12 | 2024-09-24 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells |
| US20210388105A1 (en) | 2019-08-27 | 2021-12-16 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-cd39 antibodies |
| US20220372160A1 (en) | 2019-09-16 | 2022-11-24 | Surface Oncology, Inc. | Anti-CD39 Antibody Compositions and Methods |
| CN110407941B (zh) | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| CN114651013A (zh) | 2019-11-05 | 2022-06-21 | 北京加科思新药研发有限公司 | 对cd39具有特异性的结合分子及其用途 |
| CA3174202A1 (en) | 2020-04-03 | 2021-10-07 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and adoptive cell therapy |
| KR20230065974A (ko) | 2020-09-10 | 2023-05-12 | 퓨리노미아 바이오테크, 아이엔씨. | NTPDase3의 표적화를 통해 항종양 면역 반응을 강화하기 위한 방법 및 조성물 |
| US20230416394A1 (en) | 2020-11-27 | 2023-12-28 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfbeta |
-
2023
- 2023-03-02 AU AU2023227964A patent/AU2023227964A1/en active Pending
- 2023-03-02 KR KR1020247032745A patent/KR20240156633A/ko unknown
- 2023-03-02 WO PCT/CN2023/079295 patent/WO2023165561A1/en active Application Filing
- 2023-03-02 IL IL315351A patent/IL315351A/en unknown
- 2023-03-02 US US18/177,729 patent/US11970543B2/en active Active
- 2023-03-02 EP EP23762959.7A patent/EP4486785A1/en active Pending
- 2023-03-02 AR ARP230100529A patent/AR128688A1/es unknown
- 2023-03-02 TW TW112107685A patent/TW202340243A/zh unknown
- 2023-03-02 MX MX2024010646A patent/MX2024010646A/es unknown
- 2023-03-02 CN CN202380024645.6A patent/CN119173535A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL315351A (en) | 2024-11-01 |
| AU2023227964A1 (en) | 2024-09-19 |
| KR20240156633A (ko) | 2024-10-30 |
| WO2023165561A1 (en) | 2023-09-07 |
| US11970543B2 (en) | 2024-04-30 |
| US20240034803A1 (en) | 2024-02-01 |
| CN119173535A (zh) | 2024-12-20 |
| TW202340243A (zh) | 2023-10-16 |
| MX2024010646A (es) | 2024-09-19 |
| EP4486785A1 (en) | 2025-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126987A2 (es) | Inmunoconjugados | |
| Agne et al. | Pex8p: an intraperoxisomal organizer of the peroxisomal import machinery | |
| WO2021222316A3 (en) | Variant nucleic acid libraries for coronavirus | |
| PE20190514A1 (es) | Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123 | |
| Dietrich et al. | Characterization of carp seminal plasma proteome in relation to blood plasma | |
| EA200970985A1 (ru) | Система экспрессии | |
| CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| WO2022271884A3 (en) | Methods and compositions relating to covid antibody epitopes | |
| AR093186A1 (es) | Proteinas de union al antigeno cd27l | |
| AR128688A1 (es) | Anticuerpos anti-cd39 y uso de los mismos | |
| CO5601037A2 (es) | Anticuerpos anti-a beta y sus usos | |
| Jarray et al. | Disruption of phactr-1 pathway triggers pro-inflammatory and pro-atherogenic factors: New insights in atherosclerosis development | |
| WO2020210440A1 (en) | Recombinant elastin and production thereof | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| MX2021014952A (es) | Molecula de union especifica para cd73 y uso de la molecula de union. | |
| PE20220489A1 (es) | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso | |
| CL2019003406A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| WO2023023190A3 (en) | Single domain antibodies for sars-cov-2 | |
| WO2023076420A3 (en) | Multispecific sars-cov-2 antibodies and methods of use | |
| CN104232588A (zh) | 一种抗肝纤维化药物高通量筛选细胞模型的构建及应用 | |
| AR128689A1 (es) | Anticuerpos 3e10 humanizados, variantes y fragmentos de unión al antígeno de los mismos | |
| Li et al. | Identification of cathepsin B from large yellow croaker (Pseudosciaena crocea) and its role in the processing of MHC class II-associated invariant chain | |
| BR112022011357A2 (pt) | Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo | |
| PE20230090A1 (es) | Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos |